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Endocytosis of the Flaviviridae viruses, hepatitis C virus, GB virus
Cyhepatitis G virus, and bovine viral diarrheal virus (BVDV) was
shown to be mediated by low density lipoprotein (LDL) receptors
on cultured cells by several lines of evidence: by the demonstration
that endocytosis of these virus correlated with LDL receptor activ-
ity, by complete inhibition of detectable endocytosis by anti-LDL
receptor antibody, by inhibition with anti-apolipoprotein E and
-apolipoprotein B antibodies, by chemical methods abrogating
lipoproteinyLDL receptor interactions, and by inhibition with the
endocytosis inhibitor phenylarsine oxide. Confirmatory evidence
was provided by the lack of detectable LDL receptor on cells known
to be resistant to BVDV infection. Endocytosis via the LDL receptor
was shown to be mediated by complexing of the virus to very low
density lipoprotein or LDL but not high density lipoprotein. Studies
using LDL receptor-deficient cells or a cytolytic BVDV system
indicated that the LDL receptor may be the main but not exclusive
means of cell entry of these viruses. Studies on other types of
viruses indicated that this mechanism may not be exclusive to
Flaviviridae but may be used by viruses that associate with lipopro-
tein in the blood. These findings provide evidence that the family
of LDL receptors may serve as viral receptors.
Hepatitis C virus (HCV), the principal viral cause of chronichepatitis, is not readily replicated in cell culture systems,
and, as yet, no information on cell receptors for the virus is
available. However, several observations from studies on the role
of HCV in mixed cryoglobulinemia (1–3) have provided some
insights to HCV entry into cells.
Mixed cryoglobulinemia is a systemic vasculitis associated with
cold-precipitable immunoglobulins in the blood. During the past
5 years, a strong association of HCV infection with mixed
cryoglobulins has been established (4), and the specific concen-
tration of HCV in type II mixed cryoglobulins that consist of
polyclonal IgG and monoclonal IgM has been demonstrated (1).
It also was shown that very low density lipoprotein (VLDL) is
selectively associated with HCV in type II cryoglobulins (2). In
studies on the cutaneous vasculitic lesions in type II cryoglob-
ulinemia using in situ hybridization (ISH), the HCV RNA virion
form (positive strand) but not the putative replicative form
(negative strand) of the virus was detected in keratinocytes in
lesions but not normal skin of the same patients (3). Further-
more, it was demonstrated that LDL receptors were up-
regulated on keratinocytes in cutaneous vasculitis lesions com-
pared with normal skin (3). These observations and the finding
that anti-b lipoprotein precipitates HCV from infected serum
(5) suggested that the low density lipoprotein (LDL) receptor
also may be a receptor for HCV complexed to VLDL or LDL.
This hypothesis led to this study to determine whether the LDL
receptor is also a receptor for HCV and other members of the
family of viruses Flaviviridae.
Materials and Methods
Reagents, Antisera Virus Stocks, and Cell Lines. Cyclohexanedione,
phenylarsine oxide (PAO), heparin sulfate, and EGTA were pur-
chased from Sigma; 1,19-dioctadecyl-3,3,39,39-tetramethylindocar-
bocyanine iodine (DiI) was purchased from Molecular Probes.
Purified IgG 2a mouse monoclonal anti-LDL receptor antibody (C7
clone) was obtained from Oncogene Scientific Products (Cam-
bridge, MA). Anti-bovine viral diarrhea virus (BVDV) envelope
antibody bovine serum, a49, was provided by Marc S. Collett (Viro
Pharma, Malvern, PA). Mouse monoclonal IgG 2a anti-CD-16,
anti-CD-19, and anti-transferrin (CD71) were purchased from
Immunotech (Hialeah, FL). Anti-m was purchased from Jackson
ImmunoResearch. Anti-apolipoprotein (aapo) E and aapo A-I
were purchased from Cortex Pharmaceuticals (San Leandro, CA);
aapo B was purchased from Sigma. Purified mouse monoclonal
IgG aapo E (1D7), aapo A-I (3G10), and aapo B (4G3) were
purchased from the University of Ottawa Heart Institute. F(ab9)2,
an antibody fragment with two antigen-combining sites, prepara-
tions of mouse IgG were prepared by treating the mouse mono-
clonal antibodies from 30 minutes to 10 hours with 3% pepsin
(Sigma) (pH 3.5) at 37°C. The F(ab9)2 fragments were isolated by
column chromatography using a HR 10y30 Superose 12 column
(Amersham Pharmacia). Bovine viral diarrhea virus-free donor calf
serum was purchased from Boyt Veterinary Laboratory (Neosho,
MO). Potassium bromide density gradient ultracentrifugation was
used for preparation of VLDL, LDL, and high density lipoprotein
(HDL) from normal sera, and these lipoproteins complexed to
HCV from infected sera. The VLDL band [density (d) 5 0.95–1.006
gyml], the LDL band (d 5 1.019–1.063), the HDL band (d 5
1.063–1.21 gyml), and HCV free of lipoproteins (d . 1.21) were
isolated by aspiration and then dialyzed against Hanks’ balanced
salt solution (Sigma) containing 0.01% EDTA. Isolated HCV-
VLDL was dissociated to HCV and VLDL by treatment with
deoxycholate and fractionated by sucrose density gradient ultra-
centrifugation as described (6). The high density HCV fraction, free
of lipoproteins, was further fractionated by column chromatogra-
phy on a lecithin pretreated Superose 6 (Amersham Pharmacia).
The peak of HCV present in the void volume was contaminated
with small amounts of immunoglobulins that were removed by using
immobilized rProtein A (Repligen). Immoblotting (dot blots) to
detect small amounts of protein was performed as described (7).
Sensitivity of the assay was 100 pg for IgG and IgM and 200 pg for
apolipoproteins B and E. Lipoproteins were quantitated by Lowry
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assay using commercial kits (Sigma). Highly purified VLDL, LDL,
and HDL were purchased from Cortex. Labeling of LDL with DiI
was performed as described (8).
Infected human sera were used as stocks for HCV (3 3 108
genomic equivalents per millimeter [gEyml]), GB virus Cyhepatitis
G virus (HGV) (2 3 109 gEyml), and herpes simplex virus (HSV).
BVDV strains NY-1 and National Animal Disease Laboratory
(NADL) and vesicular stomatitis virus (VSV), Indiana strain, and
respiratory syncytial virus were obtained from American Type
Culture Collection (Rockville, MD). Bovine turbinate (BT) and
kidney (MDBK) cell lines, Hep G2, a hepatoma cell line that is
biochemically similar to hepatocytes (9), Daudi, a B cell lympho-
blastoid cell line, the Molt-4 T cell line, HEp 2, a squamous
carcinoma cell line, and normal fibroblasts (MRC-5) were obtained
from the American Type Culture Collection. The B lymphocyte
lines G4 and E11 were generated from fusion of F3B6 human-
mouse heterohybridoma with peripheral B cells from patients with
type II cryoglobulinemia and rheumatoid arthritis, respectively.
Development of the 35G6 peripheral B cell line, cloned from a
normal patient, was previously described (10). Four LDL receptor
negative cell lines, GM00488C, GM02000G, GM00701C, and
GMO3040B, were obtained from the National Institute of General
Medical Sciences, Human Genetics Mutant Cell Repository, Co-
riell Institute for Medical Research (Camden, NJ). Cells resistant
to infection with BVDV (CRIB) were provided by R. O. Donis
(University of Nebraska, Lincoln, NE).
LDL Receptor Assays. Cells were cultured in RPMI medium 1640
supplemented with 10% BVDV-free bovine calf serum or
expression of the LDL receptor was up-regulated by culturing for
24 hours in RPMI medium 1640 supplemented with 10% li-
poprotein-deficient BVDV-free medium. The cells then were
washed twice with PBS (pH 7.2). Cytospin preparations were
made, fixed with acetone, and blocked with 5% normal mouse
serum, and the LDL receptor was visualized by incubating the
slides with 5 mgyml purified IgG 2a monoclonal anti-LDL
receptor antibody followed by a 1:50 dilution of FITC-labeled
goat anti-mouse [F(ab9)2] second antibody (Jackson ImmunoRe-
search). The demonstration of LDL receptors on adherent cells,
MDBK, CRIB, fibroblasts, Hep G2, and HEp 2 was performed
in the same manner except monolayers of cells were cultured and
fixed on slides.
Demonstration of endocytosis of DiI-LDL by cells was per-
formed by incubation of 2 3 105 cells for 2 hours at 37°C in 5% CO2
with 20 mgyml DiI-LDL as described (11). The cells were washed
twice with cold PBS and were fixed with 1% buffered paraformal-
dehyde, and cytospin preparations were made for fluorescent
microscopic studies or cells in suspension were analyzed by flow
cytometry. Flow cytometric analysis was performed by using the
Epic XL-MCL cytometer (Coulter) using a 575 BP filter. Nonspe-
cific binding of DiI-LDL was determined by using DiI-LDL treated
with cyclohexanedione and was subtracted from the DiI-LDL
binding to give specific DiI-LDL binding to cultured cells.
HCV RNA and Endocytosis Assays. HCV RNA, reverse transcriptase
(RT)–PCR, and ISH assays were performed as described (12).
Specificity of the ISH method for HCV was determined by
comparing monolayers of human fibroblasts inoculated with
either 3 3 107 gEyml HCV or dilutions of adenovirus or
respiratory syncytial virus that produced pathologic changes in
cells at 24 hours. After incubation for 24 hours at 37°C, the
cultures were assayed for HCV RNA by ISH. The endocytosis
assay for HCV was performed as described (12). Daudi cells (5 3
105 cells) were inoculated with 3 3 107 gE HCV or GB virus
CyHGV, were incubated for 3 hours at 37°C, were washed three
times, and were assayed for intracytoplasmic HCV RNA or GB
virus CyHGV RNA by ISH. RT-PCR and ISH assays for GB
virus CyHGV RNA were performed as described (13). The same
methodology also was used for studies with HCV-lipoprotein
recombinants. One hundred micrograms each of normal VLDL,
LDL, HDL or cyclohexanedione-treated VLDL, or LDL were
incubated with 106 gE HCV free of lipoproteins and immuno-
globulins for 30 minutes at 37°C and then were added to the
Daudi cells.
For cytolytic viruses, BVDV, NADL, VSV, and HSV, various
dilutions of the respective viruses were incubated with monolayers
of cells at 4°C for 1 hour, were washed three times with cold PBS,
and were incubated with fresh medium. Virus dilutions that pro-
duced complete cytolysis at 72 hours for BVDV and VSV and 48
hours for HSV were selected. Immunofluorescent detection of
intracytoplasmic BVDV was performed on acetone-fixed slides by
using 1:50 dilutions of anti-BVDV serum and a FITC-labeled
anti-bovine second antibody. The presence of BVDV in cells was
confirmed by RT-PCR using BVDV specific primers (14).
Inhibition Studies. Blocking of LDL receptor with various dilu-
tions of antibodies (anti-LDL receptor, 5–20 mgyml; control
antisera, 5–20 mgyml) or inhibitors was performed by pretreat-
ment of cells with various concentrations of antisera or inhibitor
for 15 minutes at 37°C and inoculating with virus without
washing the cells. Additions of antisera during incubation period
were made at 45-minute intervals. Treatment of LDL and VLDL
with cyclohexanedione was performed as described (15). In
experiments with cytopathic virus, cells were pretreated with 50
mgyml of anti-LDL receptor antibody for 30 minutes at 4°C
before inoculation with virus at 4°C.
Inhibition of endocytosis by PAO was assessed by pretreating
cells with a range of final PAO concentration of 0.1–100 mM as
described (16), and then endocytosis of LDL or HCV was evaluated
by the DiI-LDL assay or HCV-ISH, respectively, as described
earlier.
Results
Endocytosis of HCV via the LDL Receptor. We previously dem-
onstrated that endocytosis of HCV in vitro correlates with the titer
of HCV in the inoculum. The percentage of cells positive for HCV
RNA by ISH correlated directly with the number of gE of HCV per
cell as determined by RT-PCR (12). There was also a crude
correlation between intensity of ISH staining for HCV RNA and
gE HCV per cell by RT-PCR. The specificity of this ISH assay for
HCV is shown in Fig. 1. Cell cultures infected with viruses other
than HCV were negative using this assay.
For a further investigation of endocytosis of HCV by cells in vitro,
a variety of human cell cultures (see Materials and Methods) were
demonstrated to have LDL receptors with the use of anti-LDL
receptor antibody or DiI-LDL uptake. These cell lines then were
inoculated with a high titer HCV-positive human serum. Intracel-
lular HCV RNA then was detected by using ISH. To determine
whether endocytosis of HCV correlated with the level of LDL
Fig. 1. Demonstration of the specificity of the ISH method for HCV. (A) HEp
2 cells 24 hours after inoculation with HCV. The brown staining indicates the
presence of positive-strand HCV. (B and C) HEp 2 cells incubated with respi-
ratory syncytial virus or adenovirus, respectively, show no staining for HCV
using the same ISH method as in A. Note the cytopathic effect of these viruses
on the Hep 2 monolayers. Original magnification, 3500.
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receptor expression on cells, the well known modulatory effect of
lipoproteins on the LDL receptor was used to increase the number
of LDL receptors (up-regulate) on cells by culturing in lipoprotein-
deficient media. Relative differences in endocytosis of LDL by
various cultured cell lines could be demonstrated by the specific
uptake of DiI-LDL. The specific DiI-LDL uptake of Hep G2 cells
as shown in Table 1 was four times greater than of the peripheral
B cell line, G4, without up-regulation.
Up-regulating these B cells produced a LDL uptake equivalent
to that of the Hep G2 cells without up-regulation. These results
were confirmed by immunofluorescent studies using anti-LDL
receptor antibody staining and DiI-LDL uptake (Fig. 2 A and B).
Up-regulation of the LDL receptors of G4 cells resulted in
70–80% of cells staining positive for the LDL receptor, a result
that was similar to the 70–80% cells positive for the LDL
receptor on Hep G2 cells (Fig. 3E) and Daudi cells (Fig. 3G),
also known to have higher densities of LDL receptor (11).
The percentage of cells positive for HCV by ISH was shown to
correlate with the percentage of cells positive for LDL receptor by
immunofluorescence using anti-LDL receptor antibody or DiI-
labeled LDL. Endocytosis of HCV by peripheral B cells that
showed 5–30% weakly positive cells in routine culture (Fig. 3A)
when up-regulated showed a percentage of positive cells and an
intensity of staining (Fig. 3B) comparable to Hep G2 cells (Fig. 3E)
and Daudi cells (Fig. 3G) that were each 70–80% positive.
Direct evidence that the LDL receptor-mediated endocytosis
of HCV was obtained by inhibiting endocytosis with anti-LDL
receptor antibody. The endocytosis of HCV could be inhibited
in a dose-dependent manner by preincubating the cells with
anti-LDL receptor antibody. At sufficient concentrations of
anti-LDL receptor antibody, complete inhibition of endocytosis
of the virus could be demonstrated for both G4 and Hep G2 cells
(Fig. 3 C–F). Similar results were obtained by using infected
serum or VLDL-HCV complexes isolated from type II cryo-
globulins as the inoculum in these experiments. No inhibition
was observed with control mouse IgG 2a or antisera to specific
cell surface antigens at a concentration up to 20 times the lowest
inhibiting concentration of anti-LDL receptor: antisera to m
heavy chain, CD-19, and CD-16 surface antigens on peripheral
B cells and Daudi cells and antiserum to transferrin receptor on
Hep G2 cells did not inhibit the endocytosis of HCV by these
cells. Moreover, treatment of Daudi cells with the endocytosis
inhibitor PAO at 2 mM concentration completely inhibited the
endocytosis of HCV (Fig. 3 G and H).
The role of the LDL receptor in the endocytosis of HCV was
confirmed by demonstrating competitive inhibition with LDL
and VLDL but not HDL, which is known not to bind to the LDL
receptor. With use of hepatoma cells (Hep G2) or B cells (G4
and E11), 25–100 mgyml of LDL or VLDL completely inhibited
endocytosis of HCV whereas concentrations of HDL up to 200
mgyml (a 5- to 20- and 10- to 40-fold molar excess over LDL and
VLDL, respectively) did not inhibit. Treatment of LDL or VLDL
with cyclohexanedione, which is known to alter a critical arginine
residue in the LDL receptor binding site of apolipoproteins E
and B (15), the main apolipoproteins found in VLDL and LDL,
respectively, eliminated the inhibition by LDL or VLDL. More-
over, 25 unitsyml of heparin sulfate or 2 mM EGTA inhibited
endocytosis of HCV. Both are known inhibitors of LDL receptor
endocytosis of lipoprotein (17).
To determine whether lipoproteins were involved in the
endocytosis of HCV, we performed inhibition studies using
various previously characterized antisera to apolipoproteins
[aapo E, ID7 (18); aapo B, 4G3 (19); and aapo A-I, 3G10 (20)].
F(ab9)2 fragments were prepared and were used for all of the
studies; inhibitory activities of the preparations were tested
against DiI-labeled VLDL, LDL, and HDL isolated from a
normal serum. Optimum F(ab9)2 antibody concentrations and
conditions for inhibition of endocytosis were determined. Op-
timum conditions required addition of F(ab9)2s after pretreat-
ment during the incubation period, and both aapo E and aapo
B were required for maximal inhibition of VLDL endocytosis,
whereas aapo B was sufficient for maximal inhibition of LDL
endocytosis. Under these conditions, the maximum inhibition of
HCV endocytosis achieved was 65%, with the remaining positive
cells showing only trace staining. Pretreatment with aapo A-I
gave 10% inhibition, with the remaining positive cells showing no
decrease of staining compared with the control. The addition of
aapo A-I during incubation did not increase inhibition. The
finding that both aapo E and aapo B were required and that
additional F(ab9)2s during the incubation increased inhibition
was most likely attributable to the complexity of VLDL metab-
olism and dissociation of F(ab9)2s binding at 37°C. Hence, it
could not be determined whether VLDL alone or both VLDL
and LDL mediated endocytosis of HCV. Moreover, because
complete inhibition could not be achieved, direct endocytosis of
HCV by the LDL receptor could not be excluded.
Endocytosis experiments of isolated HCV-lipoprotein complexes
and recombination experiments with HCV and lipoproteins pro-
vided more definitive data on the role of lipoproteins in endocytosis
of HCV via the LDL receptor. Isolation of HCV by dissociation of
HCV-VLDL complexes was unsuccessful; however, density gradi-
ent fractionation of a serum containing a high concentration of
HCV produced not only HCV lipoprotein fractions but also a high
density HCV fraction free of lipoprotein. Immunoglobulins con-
taminating the latter fraction were removed, providing a ‘‘free’’
HCV fraction for recombinant studies. Comparison of endocytosis
of the various fractions is shown in Table 2. The HCV-VLDL and
HCV-LDL, but not the HCV-HDL or high density HCV, fractions
were endocytosed. Addition of VLDL or LDL but not HDL,
isolated from normal serum, to the free HCV resulted in restora-
tion of endocytosis. Cyclohexanedione treatment of the VLDL or
LDL abrogated the rescue (data not shown).
Further studies were performed by using the LDL receptor-
deficient fibroblast cells (21). Inoculation of these cells with
HCV showed only weak endocytosis that could not be increased
with preincubation of cells in lipoprotein deficient medium nor
inhibited by anti-LDL receptor antibody (data not shown).
Fig. 2. (A) Demonstration of the LDL receptor on up-regulated G4 cell using
anti-LDL receptor antibody (green fluorescent staining). The signal was very
weak in ’30% of G4 cells without up-regulation of the LDL receptor (not
shown). (B) Demonstration of the uptake of 5 mg of DiI-LDL by G4 cells that
have up-regulated LDL receptors as in A. (C) Inhibition of 5 mg of DiI-LDL
endocytosis by 303 excess of unlabeled LDL. (D) Same field as C by phase
contrast microscopy. Original magnification, 3500.
Table 1. Uptake of LDL by cultured cells
Cell line Culture medium Treatment
Mean
fluorescence
G4 Routine* None 0.8 6 0.4
G4 Routine DiI-LDL 4 6 2.0
G4 Lipoprotein deficient† DiI-LDL 16 6 7
Hep G2 Routine None 3 6 1
Hep G2 Routine DiI-LDL 16 6 5
*RPMI with 10% fetal bovine serum.
†RPMI with lipoprotein-deficient serum.
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Furthermore, this low level endocytosis could not be competi-
tively inhibited with excess VLDL.
Replication of Endocytosed HCV. Replication of HCV has been
reported in Hep G2 and Daudi cell cultures. Extended cultures
of Hep G2, Daudi, and G4 cells were tested serially by ISH for
evidence of replication. In the Hep G2 cells, only positive-strand
HCV was detected in the cells up to 1 week, but, at 3 weeks, 85%
of the cells contained positive-strand HCV and 65% contained
negative-strand HCV (data not shown). At 4 weeks, the cells
were negative for HCV. In Daudi cells, only positive strand was
detected through day 10, but on days 15 and 20, both positive-
and negative-strand genome sequences were present in 80%
cells. The cells died in the fourth week of culture. Only the
positive strand of HCV was detected in G4 cells up to 1 week;
the cells died after 1 week.
Endocytosis of Other Flaviviridae Viruses. We investigated commer-
cial bovine sera that were known to be contaminated with the
pestivirus BVDV (22, 23). Human cell lines routinely cultured in
media containing bovine serum were found to be positive for
intracytoplasmic BVDV by immunofluorescence using anti-
BVDV antibody. The presence of BVDV was confirmed by
RT-PCR using BVDV-specific primers. Negative-strand BVDV
was not detected in cells nonpermissive to infection. BVDV-
positive human nonpermissive cells became negative over a
4-week culture period in noncontaminated media. Endocytosis
of BVDV by nonpermissive cultured cells could be inhibited
completely with anti-LDL receptor antibody but not with the
control anti-transferrin receptor antibody (data not shown for
this set of experiments).
With use of the cytopathic NADL strain of BVDV and
permissive cells, BT or bovine kidney (MDBK) cells, anti-LDL
receptor antibody but not control antiserum inhibited the cyto-
pathic effect and positive fluorescence at 3 days (Fig. 4 A–D).
Five days after infection, there was complete cytolysis of both the
inhibited and control cells. Similar studies using VSV and HSV
showed no inhibition of infection by anti-LDL receptor antibody
for HSV (Fig. 4 E, F, and I) but some inhibition for VSV at 48
hours, which was no longer apparent at 72 hours (Fig. 4 G–I).
Additional evidence for endocytosis of BVDV by LDL recep-
tor was obtained by using a cell line (CRIB) resistant to BVDV
that was derived from a permissive bovine kidney cell line
(MDBK). As illustrated in Fig. 5, the CRIB cells that do not
permit entry of BVDV (24) also do not endocytose LDL. The
CRIB cells were negative for LDL receptors by immunofluo-
rescence using anti-LDL receptor antibody (data not shown).
However, the absence of DiI-LDL staining (see Fig. 5) is a more
sensitive indication of the absence of LDL receptor and LDL
receptor endocytosis because accumulation of DiI-LDL occurs
from the rapid turnover of LDL by LDL receptor in the course
of cholesterol metabolism.
A third member of the Flaviviridae family, GB virus CyHGV,
was reported to associate with lipoproteins in the blood (25).
Evidence also was obtained for LDL receptor-mediated endo-
cytosis of this virus, as illustrated in Fig. 6.
Discussion
Several lines of evidence were presented supporting the hypothesis
that HCV and other members of Flaviviridae are endocytosed via
Fig. 3. (A) HCV ISH of HCV-inoculated G4 cells that were not up-regulated. Dark brown cytoplasmic staining indicates the presence of the virion form of HCV;
only ’30% of the cells are weakly positive. (B) By contrast, HCV was present in most cells in cultures in which the LDL receptor was up-regulated before HCV
exposure. Original magnification for A and B, 3500. (C) High-power view of HCV-infected G4 cells with up-regulated LDL receptor as in B. (D) G4 cells prepared
as in B and C were pretreated with anti-LDL receptor antibody. Blocking of the receptor by the antibodies decreased the uptake of the virus below the detection
limit of ISH. Control antisera (see text) did not have such blocking effect (not shown). Original magnification for C and D, 31,250. (E) Uptake of HCV by Hep G2
hepatoma cell line is shown by ISH. (F) Blocking the LDL receptor with its specific antibody completely prevented the endocytosis of the virus, as demonstrated
by ISH in E. Original magnification for E and F, 3500. (G) Incubation of Daudi cells with HCV-positive serum resulted in positive staining by ISH. (H) Pretreatment
of Daudi cells with 2 mM PAO completely inhibited the endocytosis of HCV, as illustrated in G. Original magnification for G and H, 31250.
Table 2. Comparison of endocytosis of HCV in lipoprotein
fractions and the high density HCV fraction
Fraction
HCV,
gEyml
Lipoprotein,
concentration,
mgyml
Endocytosis of 5 mg
DiI-labeled fraction
mean fluorescence,
log scale
Endocytosis of
1 3 106 gE
HCV from each
fraction,
percent cell
positive,
intensity of
staining
VLDL 2.5 3 106 0.48 8.49 90%, 11
LDL 2.9 3 106 1.47 9.98 75%, 1
HDL 8.3 3 106 2.56 1.88 0
d . 1.21 3.9 3 106 2 2 0
11, Moderately positive; 1, weakly positive.
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the LDL receptor. Endocytosis of HCV was shown to correlate with
cell LDL receptor activity by experimental modulation of LDL
receptor activity and with the striking demonstration that the CRIB
cell line, resistant to infection with BVDV for unknown reasons
(24), lacked detectable LDL receptor activity. Direct evidence for
the hypothesis was provided by inhibiting endocytosis of HCV,
BVDV, and GB virus CyHCV with anti-LDL receptor antibody.
Moreover, known biochemical inhibitors of LDL endocytosis and
the endocytosis inhibitor, PAO, inhibited LDL receptor-mediated
Fig. 4. (A) Demonstration of infection of BT cell monolayers by cytopathic BVDV (NADL strain) after 72 hours of incubation by immunofluorescence using anti-BVDV
(green fluorescent staining). (B) Same field as in A by phase contrast microscopy. (C) Preincubation of BT cell monolayers with anti-LDL receptor antibody has completely
prevented the infection (shown in A) of BT cells, as seen after 72 hours of culturing. Same detection method as in A. (D) Phase contrast photomicrograph of the same
field as in C. Original magnification for A–D, 3500. (E) Inoculation of MRC-5 fibroblasts with HSV resulted in widespread cytolysis and destruction of the monolayer
after 48 hours. (F) Pretreatment of the monolayers with anti-LDL receptor antibody, using the same protocol as in C, did not prevent cytolysis and cell death. (G)
Incubation of MRC-5 cells with dilutions of VSV also resulted in cytopathy and deterioration of the monolayer. (H) Pretreatment with anti-LDL receptor showed some
inhibition of the destruction of the cells. Pretreatment and incubation conditions were as in C and F. (I) Control MRC-5 cell monolayer treated with anti-LDL receptor
antibody as in C, F, and H but not inoculated subsequently with virus. Note the uniformity and healthy appearance of these fibroblasts. Original magnification for E–I,
3250.
Fig. 5. (A) Intense uptake of DiI-LDL by a monolayer of the MDBK cells. (B) Phase
contrast microscopy of the same field as A. (C) The lack of endocytosis of DiI-LDL
wasdemonstratedintheCRIBcell linethat is resistanttoBVDVinfection. (D)Same
field as in C with phase contrast. (E) Demonstration of the infection of MDBK cells
with the NY-1 noncytopathic strain of BVDV after 72 hours of incubation by
immunofluorescence using anti-BVDV (green fluorescent staining). (F) Phase
contrast picture of E. (G) No BVDV was demonstrated by immunofluorescence in
the BVDV-resistant CRIB cells that have been incubated with the virus. Conditions
were as in E–F. (H) Phase contrast for G. Original magnification for A–H, 3500.
Fig. 6. (A) Daudi cells inoculated with HGV show the presence of HGV virion
in the cytoplasm using ISH specific for this virus. (B) Preincubation of the cells
with anti-LDL receptor antibody decreased the uptake of this virus below the
detection limit of ISH. Original magnification for A and B, 31,250.
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endocytosis of these viruses. The reports that up-regulation of LDL
receptors facilitated persistent HCV infection in vitro (26) and the
induction of HCV binding with transfection of the LDL receptor
gene in COS-7 cells that were unable to bind HCV (27) are
consistent with these findings.
Evidence also was presented that endocytosis of HCV via the
LDL receptor was mediated by the complexing of HCV to VLDL
or LDL. Although, HCV also appeared to complex with HDL in
the serum to the same extent as VLDL and LDL, there was no
evidence of HDL-mediated endocytosis of HCV. It could not be
determined from the studies performed whether the low level of
endocytosis of HDL compared with those of VLDL and LDL,
as shown by cytometric studies with DiI-labeled lipoproteins, was
responsible for the absence of detectable levels of HDL-
mediated endocytosis of HCV.
The complete inhibition by anti-LDL receptor antibody of
HCV endocytosis by a variety of cells in vitro suggests that the
LDL receptor may be the main mechanism for entry of HCV into
cells. However, the detection of small amounts of intracellular
HCV in LDL-deficient fibroblasts inoculated with HCV that
could not be inhibited by anti-LDL receptor antibody suggested
that receptors not related to the LDL receptor mediate viral
entry in these cells. Furthermore, the finding that there was only
a delaying effect of anti-LDL receptor antibody on the cyto-
pathic effect of the NADL strain of BVDV indicates that
receptors for BVDV other than LDL receptors or low affinity
LDL receptors were present. This finding is consistent with the
observations of Flores and Donis (24) that CRIB cells could be
infected with high concentrations of BVDV. Hence, the LDL
receptor may be the main but not exclusive means of entry of
these viruses into these cells.
The evidence of HCV replication in Hep G2 and Daudi cells,
although transient, suggests that endocytosis of HCV mediated
by the LDL receptor can result in infection. Whether this route
of entry can result in a productive infection in vivo and whether
all members of the Flaviviridae family of viruses use this
mechanism of cell entry remain to be determined. The evidence
presented in this study that VSV also may be endocytosed by the
LDL receptor appears to be contrary to an earlier study (28) that
found interferon-a induces a soluble LDL receptor fragment
that inhibits VSV infection but concluded that the LDL receptor
was not a receptor for VSV. The latter conclusion was reached
because VSV was found to infect LDL receptor-deficient fibro-
blasts. From our finding that entry of HCV into LDL receptor-
deficient fibroblast was independent of the LDL receptors, it is
apparent that Fischer et al. (28) did not present definitive
evidence that VSV was not endocytosed by means of the LDL
receptor because receptors for VSV other than LDL receptors
may have been present on those cells.
LDL receptor-mediated endocytosis may not be exclusive to
Flaviviridae. Rather, this mechanism may be used by all viruses
that can associate with VLDL or LDL in the blood. The reported
association of VSV with lipoproteins in the blood, particularly
VLDL (29), is consistent with this notion.
Thus far, there only has been indirect evidence of in vivo
endocytosis of HCV mediated by the LDL receptor, that is, the
apparent endocytosis of HCV by keratinocytes in the inflammatory
skin lesions of patients with type II cryoglobulinemia (3). In this
study, evidence that BVDV contaminated media from bovine
serum is endocytosed by a wide variety of human cells nonpermis-
sive to BVDV infection suggests that this mechanism may explain
the presence of positive-strand HCV that has been widely reported
in human nonhepatic cells, particularly peripheral blood mononu-
clear cells. This mechanism must be considered before assigning
HCV tropism for tissues other than the liver where clear evidence
for HCV replication has been demonstrated.
The potential involvement of the LDL receptor in HCV
infection has implications for the current therapy of HCV
infection and also provides the rationale for a new approach to
therapy—specifically, administration of anti-LDL receptor an-
tibody or analogues of the LDL receptor binding site of apoli-
poproteins B and E. The effect of IFNa, the current therapy for
HCV infection, may be mediated in part by the down-regulation
of LDL receptors. IFNa is known to induce IL-1 receptor
antagonist (30), which blocks the IL-1 receptor-mediated stim-
ulation by IL-1. Because IL-1 is known to increase LDL receptor
activity (31), IFNa would indirectly cause a down-regulation of
LDL receptor activity by stimulating IL-1 receptor antagonist
production, thereby decreasing IL-1 receptor-mediated stimu-
lation by IL-1.
It has been reported that a minor group of human rhinovirus
(HRV2) (32) and Rous sarcoma virus A (33) enters cells via the
LDL receptor-related protein. In the latter report, evidence was
presented that a viral envelope moiety binds to LDL receptor-
related protein. Our study provides evidence that the family of
LDL receptors may serve as viral receptors.
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